Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. Apontis Pharma AG
  6. News
  7. Summary
    APPH   DE000A3CMGM5

APONTIS PHARMA AG

(APPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : APONTIS PHARMA AG: Notification on the implementation of stabilization measures

05/28/2021 | 02:06pm EDT
DGAP-News: APONTIS PHARMA AG / Key word(s): Miscellaneous 
APONTIS PHARMA AG: Notification on the implementation of stabilization measures 
2021-05-28 / 20:05 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR 
JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE 
APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. 
28 May 2021 
APONTIS PHARMA AG 
Disclosure in accordance with Article 5 para. 4 lit. (b) and para. 5 of Regulation (EU) No 596/2014 of the European 
Parliament and of the Council on market abuse ("Market Abuse Regulation") of 16 April 2014 and in accordance with 
Article 6 para. 2 of the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 on the implementation of 
stabilisation measures 
Following the pre-stabilisation announcement dated 29 April 2021, the stabilisation manager mentioned below has 
informed APONTIS PHARMA AG, Monheim am Rhein, Germany, (contact person: Sven Pauly; Telefon: +49 2173 89 55 4900) that 
stabilisations (within the meaning of Article 3 para. 2 lit. (d) of the Market Abuse Regulation) have taken place with 
respect to the offer of the following securities as indicated below: 
The Securities: 
Issuer:                               APONTIS PHARMA AG 
Guarantor                             n/a 
(if applicable): 
Aggregate nominal amount of the offer 4,600,000 
(excluding over-allotment option): 
Description:                          Ordinary shares with no par value 
                                      ISIN DE000A3CMGM5 
Offer price:                          EUR 19.00 

Stabilisation:

Stabilisation manager:     Hauck & Aufhäuser Privatbankiers 
                           Aktiengesellschaft 
Existence, maximum size of 690,000 ordinary shares with no par value 
the over-allotment option: 
Stabilisation marketplace: Frankfurt Stock Exchange, Xetra (XETR) 

Stabilisations:

Trade date and time Purchase (P)/ Sale (S) Nominal value Execution      Currency code Market place MIC 
                                           (pieces)      price (0.0000) (ISO 4217)    (ISO 10386) 
         20.05.2021           P                    3,000        18.2500 EUR           XETR 
           17:36:02 
         20.05.2021           P                    3,000        18.2500 EUR           XETR 
           17:36:02 
         20.05.2021           P                    2,000        18.2500 EUR           XETR 
           17:36:02 
         28.05.2021           P                    1,180        17.9500 EUR           XETR 
           10:49:56 
         28.05.2021           P                       20        18.0000 EUR           XETR 
           10:49:56 
         28.05.2021           P                      132        17.9000 EUR           XETR 
           10:50:33 
         28.05.2021           P                      488        17.9500 EUR           XETR 
           10:50:33 
         28.05.2021           P                       30        18.0000 EUR           XETR 
           10:50:33 
         28.05.2021           P                      600        18.0000 EUR           XETR 
           10:50:49 
Sum           Aggregated Weighted price  Currency code 
              volume                     (ISO 4217I 
              (pieces) 
                  10,450         18.1821 EUR 

IMPORTANT NOTICE

These materials may not be, directly or indirectly, published, distributed or transmitted in or into the United States, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "Securities") of Apontis Pharma AG (the "Company") in the United States, Australia, Canada, Japan or any other jurisdiction in which such offer or solicitation is unlawful. The Securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). There will be no public offering of the securities in the United States. The Securities of the Company have not been, and will not be, registered under the Securities Act. The securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan subject to certain exceptions.

In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.), or (iii) to whom an invitation or inducement to engage in an investment activity (within the meaning of section 21 of the United Kingdom Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise be lawfully communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This publication constitutes neither an offer to sell nor a solicitation to buy any securities. The securities have already been sold. -----------------------------------------------------------------------------------------------------------------------

2021-05-28 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      APONTIS PHARMA AG 
              Alfred-Nobel-Str. 10 
              40789 Monheim 
              Germany 
E-mail:       info@apontis-pharma.de 
Internet:     https://apontis-pharma.de/ 
ISIN:         DE000A3CMGM5 
WKN:          A3CMGM 
Listed:       Regulated Unofficial Market in Frankfurt (Scale) 
EQS News ID:  1202271 
 
End of News   DGAP News Service 
=------------ 

1202271 2021-05-28

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1202271&application_name=news 
 

(END) Dow Jones Newswires

May 28, 2021 14:06 ET (18:06 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
APONTIS PHARMA AG 2.96% 19.15 Delayed Quote.0.00%
DJ INDUSTRIAL 0.68% 35061.55 Delayed Quote.13.78%
All news about APONTIS PHARMA AG
07/12PRESS RELEASE : APONTIS PHARMA marks further success in the roll-out of Single P..
DJ
07/12APONTIS PHARMA : marks further success in the roll-out of Single Pill therapy
EQ
06/18PRESS RELEASE : APONTIS PHARMA AG: Initial studies confirm that the share has a ..
DJ
06/18APONTIS PHARMA AG : Initial studies confirm that the share has a price potential..
EQ
06/10PRESS RELEASE : APONTIS PHARMA AG: Post-Stabilisation disclosure - Partial exerc..
DJ
06/10APONTIS PHARMA AG : Post-Stabilisation disclosure - Partial exercise of the Gree..
EQ
06/10PRESS RELEASE : APONTIS PHARMA AG: Notification on -2-
DJ
06/10PRESS RELEASE : APONTIS PHARMA AG: Notification on the implementation of stabili..
DJ
06/10APONTIS PHARMA AG : Notification on the implementation of stabilization measures
EQ
05/28PRESS RELEASE : APONTIS PHARMA AG: Notification on the implementation of stabili..
DJ
More news
Financials
Sales 2021 48,7 M 57,2 M 57,2 M
Net income 2021 2,90 M 3,41 M 3,41 M
Net cash 2021 28,8 M 33,8 M 33,8 M
P/E ratio 2021 55,5x
Yield 2021 -
Capitalization 163 M 191 M 191 M
EV / Sales 2021 2,75x
EV / Sales 2022 2,32x
Nbr of Employees 195
Free-Float -
Chart APONTIS PHARMA AG
Duration : Period :
Apontis Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 19,15 €
Average target price 36,00 €
Spread / Average Target 88,0%
EPS Revisions
Sector and Competitors
1st jan.Capi. (M$)
APONTIS PHARMA AG0.00%179
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246